Keytruda monotherapy in patients whose cancers are tumor mutational burden-high who have progressed following prior treatment: sBLA accepted by FDA
The FDA ( U.S. Food and Drug Administration ) has accepted and granted priority review for a new supplemental Biologics License Application ( sBLA ) for Keytruda ( Pembrolizumab ), an anti-PD-1 therap ...
read article